Patient Satisfaction With Ocrelizumab Given Under the Skin in Relapsing Multiple Sclerosis
Asks adults with relapsing-remitting multiple sclerosis how satisfied they are with ocrelizumab injections.
Plain-language title generated from the registry record
Registry title: Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis
Key facts
- Where
- Ljubljana, SloveniaSee the site
Where in Slovenia
- University Medical CentreLjubljana, SloveniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT07827586
- Record updated
- 30 October 2026
- Original description
The main purpose of the study is to assess patient-reported satisfaction with subcutaneous (s.c.) ocrelizumab administration in participants with relapsing-remitting multiple sclerosis (RRMS) who are treatment-naive, switching from intravenous (i.v.) ocrelizumab to s.c. ocrelizumab, or switching from a prior disease-modifying therapy (DMT) to s.c. ocrelizumab.Read full original descriptionShow less
A Prospective Longitudinal Multicenter, Multi-Country, Observational Study Assessing Patient Satisfaction After Subcutaneous Ocrelizumab Administration in Persons With Relapsing-Remitting Multiple Sclerosis (SONATA-MS)
The main purpose of the study is to assess patient-reported satisfaction with subcutaneous (s.c.) ocrelizumab administration in participants with relapsing-remitting multiple sclerosis (RRMS) who are treatment-naive, switching from intravenous (i.v.) ocrelizumab to s.c. ocrelizumab, or switching from a prior disease-modifying therapy (DMT) to s.c. ocrelizumab.
Inclusion: Diagnosis of RRMS according to the revised McDonald criteria (2017 or 2024 revisions); Initiation of ocrelizumab s.c in accordance with routine clinical practice and local prescribing information; The decision to initiate ocrelizumab s.c. has been made by the treating physician prior to and independently of study participation; Willingness to complete the patient-reported outcome questionnaire TASQ, where applicable.
Exclusion: Prior treatment with rituximab; Participation in any clinical study involving disease modifying therapies for multiple sclerosis during the study period or at the time of enrollment; Severe psychiatric or cognitive impairment that, in the opinion of the treating physician, would preclude informed consent, reliable participation in the study, or completion of patient-reported outcomes; Any condition which, in the opinion of the treating physician, would interfere with participation in the study or the interpretation of study results; Contraindications to ocrelizumab as per the local prescribing information; For participants participating in a Market Research and Patient Support Program (MAP), inclusion is permitted only when a cross-reference to the unique MAP patient identifier is available.